Replies to post #56986 on DNAprint Genomics (DNAG)

[Don'tDrinkTheKoolAid]

In regards to paying Lonnie 2.7 million shares is nothing when you have 1.5 BILLION shares in the bank! DNAG is used to pissing away shares on frivolous crap anyway! Anybody remember Mark Neuhaus? Dnag gave hime like 40 million shares to put their name on his race car LOL that's my favorite waste of shares their are many others just as wasteful!

[stockhlder101]

In Boston, MA> Dr. Arthur J. Sytkowski--scientist working on DNAPrint EPO.


http://salesandmarketingnetwork.com/news_release.php?ID=2015329&key=American%20Society%20of%20He...


Harvard med school. In BOSTON.. BOSTON is significant!
http://www.bidmc.harvard.edu/sites/bidmc/home.asp

Why is BOSTON significant?
Gabriel (DNAPrint CEO lives in boston:

Richard Gabriel, DNAPrint Genomics' chief executive officer and president, who accepted shares of stock instead of cash compensation when he was hired in 2002, lives in Boston. Gabriel hired the company's chief medical officer and chairman of the board, Hector J. Gomez, M.D., Ph.D., who resides in Tampa.

MANATEE FIRM MAKING LEAPS AT DNA'S DAWN
Small specialty, global fame
SARA KENNEDY
Herald Staff Writer
MANATEE - For a company whose lab work regularly solves crimes, has made international headlines about Margaret Thatcher's family heritage and is poised for growth at the scientific frontier of medicine, the vibe at DNAPrint Genomics, Inc., is surprisingly low-key.

A single, hand-lettered sign scrawled with the company's name this week was the only indication it had moved during the holidays from downtown Sarasota to a larger building at 1621 W. University Parkway in southern Manatee County. The move was necessary to provide more space for its new subsidiary, DNAPrint Pharmaceuticals, Inc., officials said.

The company's specialty is human genetics and, in particular, the genome, the content of all of an organism's hereditary information. It is a developer of genomics-based products and services.

Its forensic work and genealogy tests have made international headlines in stories broadcast on National Public Radio and in publications like The New York Times, USA Today, CBS News and London's The Sunday Times.

The company's findings figure in the investigation of sensational crimes, such as an effort to capture the so-called London Minstead Rapist, a serial rapist suspected of more than 90 assaults. Scotland Yard has turned to DNAPrint Genomics for help.

"The investigation has drawn heavily upon forensic resources for psychological and geographic crime profiles," said Matthew J. Thomas, Ph.D., the company's senior scientist and manager of laboratory operations, after a trip to London last summer. Investigators used DNA information to analyze crime scene samples, but as far as Thomas knows, they have not yet made an arrest in the case.

On Wednesday, Thomas was giving a tour of his firm's bright new laboratory and discussing one of its DNA testing products - AncestrybyDNA, a kit designed to reveal an individual's family heritage.

For a $240 fee, clients can send a swab with tissue from inside the cheek that the company uses for a basic test, which pinpoints a person's genetic heritage based on four major anthropological groups: Native American, East Asian, sub-Saharan African and Indo-European. Depending on the results, additional tests may be ordered.

The tests have produced some shocking results. One of the company's tests showed that Henry Louis Gates Jr., the famous black scholar, was half white. Another showed that Carol Thatcher, daughter of former British Prime Minister Margaret Thatcher, was of Middle Eastern descent.

Each test takes a couple days of work, Thomas said.

The company, with 20-some employees spread over the United States and Canada, stays connected to its far-flung staff through electronic communications rather than face-to-face interaction, said Emanuela I. Charlton, Ph.D., who works in customer service.

It has employees in California, Pennsylvania, Colorado and Toronto, she said, adding that it also owns a percentage of a German company called BioFrontera.

Richard Gabriel, DNAPrint Genomics' chief executive officer and president, who accepted shares of stock instead of cash compensation when he was hired in 2002, lives in Boston. Gabriel hired the company's chief medical officer and chairman of the board, Hector J. Gomez, M.D., Ph.D., who resides in Tampa.

The company's annual revenues are in the $3 million range, Gomez said in a phone interview from Tampa. He said the money the company earns is sufficient to operate its labs, but acknowledged wearily that he is "in the process of raising money all the time" for research and development.

During 2006, the company invested almost $3.2 million in research and development and $133,000 in patents to protect its technology rights, according to material the company provides investors.

Gomez said he expects the new subsidiary, DNAPrint Pharmaceuticals, Inc., launched in October 2005, will help its bottom line. It will be ramping up in the company's new quarters and the technology Gomez expects it to develop would cut by half the 12 years and $800 million currently necessary to develop a new drug.

"Now, with this technique, we can reduce the time of drug development by at least half to six years and decrease the cost by a significant number because we're minimizing mistakes," he explained.

It will attempt to design drug regimens that go beyond the one-pill-fits-all concept.

"With this technology, pharmaco-genomics, it allows us to take a sample of DNA from any patient and in the lab predict response - who is going to respond well, who will have side effects. Obviously, we can do that then by maximizing the efficiency of the drugs and minimizing the side effects, based on the person's genetic makeup," Gomez said.

Both Gomez and DNAPrint Genomics will also be part of a massive research initiative announced last month by the H. Lee Moffitt Cancer Center & Research Institute of Tampa. The center said it would partner with an affiliate of Merck & Co., Inc. pharmaceutical company to expand biotechnology research with the goal of developing personalized medicine.

Merck and Moffitt will form a for-profit company, called M2GEN, that will develop personalized cancer treatments using a patient's genetic profile.

Researchers plan to compile a database of tumor tissue and other medical information to determine why some patients respond to a treatment and others do not. The database could grow to more than 30,000 patients within five years, officials said in announcing the partnership.

"For a look at future, in 10 years, I believe you'll have (something similar to) a credit card in your pocket with all your information. It's your genetic makeup and the doctor will look at it and prescribe the medicine for you," said Gomez. "We are very excited about this."

DNAPrint Genomics was founded by Tony Frudakis, Ph.D., and acquired by another company in 2000. In 2001, Frudakis teamed with other scientists to develop new genomics products with consumer, forensic and pharmaco-genomics applications, according to Securities and Exchange Commission documents.

Since then, the company has acquired several other firms that brought scientific assets with them, such as Kenna Technologic Inc., which develops software for building computer models that mimic biological systems, and Ellipsis Biotherapeutics Corp., which specializes in genotyping and can analyze human, plant and animal tissue, SEC documents said.

Last year, the company entered into an exclusive license agreement with Harvard College at Harvard Medical School, for research and development of a diagnostic test that would identify those at risk of developing vascular diabetic complications, SEC documents reported.

[gunnabeoneday]

Brother in Arms, i find it interesting that Dr. Sytkowski has agreed to be paid in shares.....